Pharmaceuticals

First Patient Enrolled in ProstACT TARGET Study

MELBOURNE, Australia, Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care inAustralia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix's pro...

2022-09-27 05:00 2857

In commemoration of World Pharmacists Day 2022, P&G Health lauds pharmacists and the role they play in providing whole-of-body healthcare to patients

* P&G Health commemorated World Pharmacists Day 2022 across the Asia Pacific, Middle East, and Africa region through a host of activities * This includes the first ever P&G Health Middle-East Whole-Body Health Symposium over 2 days in which 12,813 participants from 111 countries took part SIN...

2022-09-26 20:08 4061

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects * Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people wit...

2022-09-26 20:00 3861

Nippon Express (China) Participates in 11th Global Pharmaceutical Cold Chain Summit

TOKYO, Sept. 26, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereinafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., participated in the three-day 11th Global Pharmaceutical Cold Chain Summit hosted by the China Federation of Logistics & Purchasing and held inChongqi...

2022-09-26 15:00 3346

Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases

Advancement highlights Everest's potential in providing first-in-class therapies to global patients with glomerular disease SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focu...

2022-09-26 08:00 4634

MGC Pharmaceuticals Successfully Developed Herbal-inspired Products for Treatment of Long COVID and COVID-19

LONDON, Sept. 21, 2022 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), is a European based bio-pharma company, focused on developing and supplying affordable (Accessible) and Ethically Produced Plant Inspired Medicines, is helping to solve the mystery of treating Lo...

2022-09-21 17:13 3936

Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference

GAITHERSBURG, Md. and SUZHOU, China, Sept. 20, 2022 /PRNewswire/ -- Sirnaomics Ltd . (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the la...

2022-09-20 22:40 4215

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

* Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections inChina * The deal brings together Melinta's innovation, Menarini's cross-regional expertise in registration and market...

2022-09-20 17:00 5032

WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA

WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received reg...

2022-09-20 10:48 3073

RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China

YANTAI, China, Sept. 19, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently announced the preliminary results of the Phase III confirmatory study of its proprietary novel fusion protein Telitacicept for th...

2022-09-19 21:00 2744

Hummingbird Bioscience Chief Scientific Officer Jerome Boyd-Kirkup to Present at the 2nd Annual VISTA Virtual Symposium

SINGAPORE, Sept. 19, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced thatJerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Offic...

2022-09-19 20:00 2032

Anyong Biotechnology's Locally Sourced 'Santé Silver Perch Essence' Fulfilling Increasing Demand in The APAC Wellness Industry

KAOHSIUNG, Taiwan, Sept. 19, 2022 /PRNewswire/ -- Taiwan-based Anyong Biotechnology, has created a locally-sourced Santé Silver Perch Essence out of ecologically farmed, certified, and traceable silver perch in major markets such asTaiwan, the United States, Singapore, and Malaysia. As consumers'...

2022-09-19 16:30 2747

MagicTouch SCB receives IDE approval for In-Stent Restenosis indication

TAMPA, Fla., Sept. 19, 2022 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval forMagicTouch  Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR).

2022-09-19 12:20 3090

Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth

SHANGHAI, Sept. 19, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific ...

2022-09-19 08:00 6415

CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®

SINGAPORE, Sept. 17, 2022 /PRNewswire/ -- CellResearch Corporation, a Singapore -based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at theUnivers...

2022-09-17 00:20 3519

Austar Lifesciences Announces 2022 Interim Results

Benefiting from the Growth in the Business Segment of Liquid and Bioprocess System and the Increased Capability of Comprehensive Integrated Solutions,its Businesses Grew Steadily Revenue Increased by 29.1% to RMB 1,104 million  Operation Highlights (RMB'000) For the six months ended 30 June ...

2022-09-15 16:53 5981

Winmate Stainless Panel PCs and Displays Solution for Food Packaging Automation

Increasing efficiencies in food processing with Winmate's hygienic and easy to clean solutions TAIPEI, Sept. 15, 2022 /PRNewswire/ -- The urgency of the global low-carbon circular economy impacted the food and drinks industry. Pushing the manufacturer to innovate while increasing their productiv...

2022-09-15 16:21 3946

SIFI TO PRESENT NEW SCIENTIFIC DATA AND LAUNCH A NEW INTRAOCULAR LENS DURING THE 40TH CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS

CATANIA, Italy, Sept. 15, 2022 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announces 3 scientific presentations on its latest innovations during the upcoming Congress of The European Society of Cataract and Refractive Surgeons (ESCRS) which will take place from 16th to 20th ...

2022-09-15 15:00 2876

Juniper Biologics Establishes Global Headquarters in Singapore

Juniper Biologics' investment will support the growth and innovation of Singapore's pharmaceutical sector SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its ...

2022-09-15 09:53 2761

Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

SUZHOU, China, Sept. 14, 2022 /PRNewswire/ --Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST003, its fir...

2022-09-14 14:18 3608
1 ... 138139140141142143144 ... 184